17.42
price down icon4.18%   -0.76
after-market アフターアワーズ: 17.42
loading
前日終値:
$18.18
開ける:
$18.04
24時間の取引高:
944.32K
Relative Volume:
0.79
時価総額:
$1.83B
収益:
$23.38M
当期純損益:
$-155.22M
株価収益率:
-7.9543
EPS:
-2.19
ネットキャッシュフロー:
$-134.36M
1週間 パフォーマンス:
-16.77%
1か月 パフォーマンス:
+10.39%
6か月 パフォーマンス:
-44.31%
1年 パフォーマンス:
-57.14%
1日の値動き範囲:
Value
$17.33
$18.77
1週間の範囲:
Value
$16.82
$21.13
52週間の値動き範囲:
Value
$13.45
$44.42

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
名前
Ideaya Biosciences Inc
Name
セクター
Healthcare (1153)
Name
電話
650-443-6209
Name
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
職員
131
Name
Twitter
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
IDYA's Discussions on Twitter

IDYA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IDYA
Ideaya Biosciences Inc
17.42 1.83B 23.38M -155.22M -134.36M -2.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 開始されました Stephens Overweight
2024-11-05 ダウングレード Leerink Partners Outperform → Market Perform
2024-10-24 開始されました UBS Buy
2024-10-15 開始されました Cantor Fitzgerald Overweight
2024-07-08 開始されました Mizuho Outperform
2024-03-08 開始されました BTIG Research Buy
2023-08-08 開始されました SVB Securities Outperform
2023-05-24 開始されました Goldman Buy
2023-04-24 アップグレード Stifel Hold → Buy
2023-03-23 開始されました Berenberg Buy
2023-02-28 開始されました RBC Capital Mkts Outperform
2022-12-28 開始されました CapitalOne Overweight
2022-10-27 開始されました Citigroup Buy
2022-08-15 ダウングレード Stifel Buy → Hold
2022-07-18 再開されました Oppenheimer Outperform
2022-03-10 アップグレード Stifel Hold → Buy
2021-09-23 開始されました Stifel Hold
2021-06-04 再開されました Robert W. Baird Outperform
2021-03-11 開始されました Guggenheim Buy
2020-10-07 開始されました Wedbush Outperform
2020-09-01 開始されました Northland Capital Outperform
2020-07-13 アップグレード JP Morgan Neutral → Overweight
2020-06-17 繰り返されました H.C. Wainwright Buy
2020-04-06 開始されました H.C. Wainwright Buy
2020-03-13 開始されました ROTH Capital Buy
2019-10-17 開始されました Oppenheimer Outperform
2019-09-10 開始されました Robert W. Baird Outperform
2019-06-17 開始されました Citigroup Buy
2019-06-17 開始されました JP Morgan Neutral
2019-06-17 開始されました Jefferies Buy
すべてを表示

Ideaya Biosciences Inc (IDYA) 最新ニュース

pulisher
May 07, 2025

Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus

May 07, 2025
pulisher
May 07, 2025

IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Ideaya Biosciences (IDYA) Advances with FDA Approval for IDE849 Trial | IDYA Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com South Africa

May 06, 2025
pulisher
May 06, 2025

Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan

May 06, 2025
pulisher
May 06, 2025

Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan

May 06, 2025
pulisher
May 05, 2025

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com

May 05, 2025
pulisher
May 05, 2025

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com

May 05, 2025
pulisher
May 05, 2025

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

May 05, 2025
pulisher
May 02, 2025

Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com

May 02, 2025
pulisher
Apr 30, 2025

Nothing is Better Than Ideaya Biosciences Inc (IDYA) stock at the moment - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

Ideaya Biosciences Inc (IDYA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

IDYA (Ideaya Biosciences Inc) has impressive results - uspostnews.com

Apr 29, 2025
pulisher
Apr 28, 2025

Investing in Ideaya Biosciences Inc (IDYA): What You Must Know - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Ideaya Biosciences Inc (NASDAQ: IDYA) Stock Forecast: An Analysis - Marketing Sentinel

Apr 28, 2025
pulisher
Apr 28, 2025

IDEAYA Biosciences CEO Fireside Chats: Key Investor Access at Two Major Healthcare Conferences - Stock Titan

Apr 28, 2025
pulisher
Apr 27, 2025

Envestnet Asset Management Inc. Sells 11,342 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Apr 27, 2025
pulisher
Apr 25, 2025

IDEAYA Biosciences Grants Stock Options To New Employees Under 2023 Inducement Plan - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

New PARG inhibitors disclosed in Ideaya patent - BioWorld MedTech

Apr 25, 2025
pulisher
Apr 25, 2025

IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 25, 2025
pulisher
Apr 22, 2025

Analysts review Ideaya Biosciences Inc’s rating - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Ideaya Biosciences Inc (IDYA) shows promising results - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Wells Fargo & Company MN Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Apr 22, 2025
pulisher
Apr 20, 2025

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event - marketscreener.com

Apr 20, 2025
pulisher
Apr 20, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Apr 20, 2025
pulisher
Apr 18, 2025

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 17, 2025

JPMorgan Chase & Co. Has $7.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Apr 17, 2025
pulisher
Apr 17, 2025

(IDYA) Trading Report - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha

Apr 16, 2025
pulisher
Apr 14, 2025

IDEAYA advances darovasertib in uveal melanoma trial By Investing.com - Investing.com Nigeria

Apr 14, 2025
pulisher
Apr 14, 2025

Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Ph - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

IDEAYA advances darovasertib in uveal melanoma trial - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - BioSpace

Apr 14, 2025
pulisher
Apr 14, 2025

Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma – Company AnnouncementFT.com - Financial Times

Apr 14, 2025
pulisher
Apr 14, 2025

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire) - Aktiellt

Apr 14, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Has $1.02 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Apr 14, 2025
pulisher
Apr 14, 2025

Geode Capital Management LLC Acquires 43,226 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Apr 14, 2025
pulisher
Apr 11, 2025

Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - The Malaysian Reserve

Apr 10, 2025
pulisher
Apr 10, 2025

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Ideaya Biosciences Announces Phase 1/2 Expansion For Ide397 And Trodelvy® Combination In Mtap-Deletion Urothelial Cancer - marketscreener.com

Apr 10, 2025
pulisher
Apr 09, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

Apr 09, 2025

Ideaya Biosciences Inc (IDYA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
大文字化:     |  ボリューム (24 時間):